NasdaqGS - Nasdaq Real Time Price USD
Guardant Health, Inc. (GH)
As of 11:26 AM EDT. Market Open.
Research Analysis
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Sep 2024) | Next Qtr. (Dec 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 17 | 15 | 14 | 17 |
| Avg. Estimate | -0.76 | -0.72 | -3.22 | -2.76 |
| Low Estimate | -0.89 | -0.87 | -3.54 | -3.82 |
| High Estimate | -0.5 | -0.38 | -2.66 | -1.71 |
| Year Ago EPS | -0.73 | -1.58 | -4.28 | -3.22 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Sep 2024) | Next Qtr. (Dec 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 20 | 20 | 22 | 23 |
| Avg. Estimate | 170.71M | 180.49M | 695.44M | 822.45M |
| Low Estimate | 166.3M | 177M | 661.31M | 788.5M |
| High Estimate | 176M | 185.59M | 700.4M | 859M |
| Year Ago Sales | 143.03M | 155.05M | 563.95M | 695.44M |
| Sales Growth (year/est) | 19.40% | 16.40% | 23.30% | 18.30% |
Earnings History
| CURRENCY IN USD | 9/30/2023 | 12/31/2023 | 3/31/2024 | 6/30/2024 |
|---|---|---|---|---|
| EPS Est. | -0.94 | -0.86 | -0.85 | -0.74 |
| EPS Actual | -0.73 | -1.58 | -0.94 | -0.84 |
| Difference | 0.21 | -0.72 | -0.09 | -0.1 |
| Surprise % | 22.30% | -83.70% | -10.60% | -13.50% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Sep 2024) | Next Qtr. (Dec 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.76 | -0.72 | -3.22 | -2.76 |
| 7 Days Ago | -0.76 | -0.72 | -3.22 | -2.76 |
| 30 Days Ago | -0.76 | -0.72 | -3.21 | -2.69 |
| 60 Days Ago | -0.74 | -0.71 | -3.22 | -2.65 |
| 90 Days Ago | -0.73 | -0.7 | -3.1 | -2.73 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Sep 2024) | Next Qtr. (Dec 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | 1 | 1 | 1 | -- |
| Up Last 30 Days | 2 | 1 | 2 | 1 |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | GH | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | -4.10% | -- | -- | 4.10% |
| Next Qtr. | 54.40% | -- | -- | 7.60% |
| Current Year | 24.80% | -- | -- | 2.50% |
| Next Year | 14.30% | -- | -- | 13.10% |
| Next 5 Years (per annum) | 29.20% | -- | -- | 11.89% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Upgrades & Downgrades
| Maintains | Leerink Partners: Outperform to Outperform | 10/17/2024 |
| Maintains | UBS: Buy to Buy | 8/21/2024 |
| Maintains | Piper Sandler: Overweight to Overweight | 8/13/2024 |
| Maintains | Citigroup: Buy to Buy | 8/8/2024 |
| Maintains | TD Cowen: Buy to Buy | 8/8/2024 |
| Maintains | Craig-Hallum: Buy to Buy | 8/8/2024 |
Related Tickers
EXAS Exact Sciences Corporation
70.31
-0.45%
NTRA Natera, Inc.
125.49
-1.01%
GRAL GRAIL, Inc.
14.45
+0.91%
TWST Twist Bioscience Corporation
45.61
+1.20%
VCYT Veracyte, Inc.
34.60
-0.36%
ILMN Illumina, Inc.
143.21
-0.47%
CDNA CareDx, Inc
25.65
-2.02%
NEOG Neogen Corporation
14.65
+0.27%
NEO NeoGenomics, Inc.
13.63
-1.41%
MYGN Myriad Genetics, Inc.
23.51
-1.71%